Top 5 Performing Stocks To Watch Right Now

Whether you have an index fund, an actively managed portfolio or a tactical portfolio, for the past year or so, your portfolio probably has been doing so-so. Not performing poorly, but not doing great either. The portfolios of most investors arent crashing; they are sort of running in place.

See Also: 7 Good Stocks with Hidden Value

But we have witnessed huge rallies in recent weeks. And also huge declines. So whats going on?

To start with, the markets peaked about a year ago. Since then, investors have been on a volatile rollercoaster that has a downward bias.

The Dow Jones industrial average peaked at 18,351 a year ago and has had two major declines since then. Each recovery rally has not been able to surpass the peak.

Top 5 Performing Stocks To Watch Right Now: Intercept Pharmaceuticals, Inc.(ICPT)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Intercept Pharmaceuticals (ICPT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    With this in mind, we picked the brains of three Motley Fool investors to gauge what biotech stock they believe investors should consider buying right now. Topping the list were mid-caps Intercept Pharmaceuticals (NASDAQ:ICPT) and Xencor (NASDAQ:XNCR), as well as biotech blue-chip Celgene (NASDAQ:CELG).

  • [By Sean Williams]

    As you can see, there’s a lot of excitement in the NASH space at the moment, and plenty of big drug stocks are itching to add a promising NASH drug to their product pipelines. But one name that continues to be left out in the cold is Intercept Pharmaceuticals (NASDAQ:ICPT).

Top 5 Performing Stocks To Watch Right Now: The Herzfeld Caribbean Basin Fund, Inc.(CUBA)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Media headlines about Herzfeld Caribbean Basin Fund, Inc. common stock (NASDAQ:CUBA) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Herzfeld Caribbean Basin Fund, Inc. common stock earned a news sentiment score of 0.00 on Accern’s scale. Accern also gave news stories about the investment management company an impact score of 48.5554072096128 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Top 5 Performing Stocks To Watch Right Now: Fiserv, Inc.(FISV)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Fiserv (NASDAQ:FISV)’s share price reached a new 52-week high and low during trading on Monday . The stock traded as low as $74.61 and last traded at $74.25, with a volume of 72911 shares changing hands. The stock had previously closed at $73.51.

  • [By Stephan Byrd]

    Envestnet Asset Management Inc. trimmed its stake in Fiserv (NASDAQ:FISV) by 22.2% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 40,589 shares of the business services provider’s stock after selling 11,568 shares during the period. Envestnet Asset Management Inc.’s holdings in Fiserv were worth $2,879,000 as of its most recent filing with the SEC.

  • [By Stephan Byrd]

    Fiserv (NASDAQ:FISV)’s share price hit a new 52-week high and low during trading on Thursday . The company traded as low as $76.14 and last traded at $74.93, with a volume of 49348 shares traded. The stock had previously closed at $75.96.

  • [By Logan Wallace]

    Fiserv (NASDAQ:FISV) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Friday.

  • [By Max Byerly]

    Segall Bryant & Hamill LLC bought a new stake in Fiserv Inc (NASDAQ:FISV) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,586 shares of the business services provider’s stock, valued at approximately $256,000.

Top 5 Performing Stocks To Watch Right Now: iShares Intermediate Credit Bond (CIU)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of ARKANSAS FINANCIAL GROUP, INC.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=ARKANSAS+FINANCIAL+GROUP%2C+INC.

    These are the top 5 holdings of ARKANSAS FINANCIAL GROUP, INC.SPDR Dow Jones Industrial Average (DIA) – 239,571 shares, 25.69% of the total portfolio. Shares reduced by 2.73%iShares Core S&P Mid-Cap (IJH) – 277,760 shares, 23.14% of the total portfolio. Shares added by 0.52%iShares 1-3 Year Credit Bond ETF (CSJ) – 400,939 shares, 18.49% of the total portfolio. Shares added by 1.16%iShares Intermediate Credit Bond ETF (CIU) – 229,423 shares, 10.93% of the total portfolio. Shares reduced by 5.93%Vanguard Mid-Cap (VO) – 82,652 shares, 5.66% of the total p

  • [By WWW.GURUFOCUS.COM]

    For the details of Allianz Investment Management LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Allianz+Investment+Management+LLC

    These are the top 5 holdings of Allianz Investment Management LLCiShares iBoxx $ Investment Grade Corporate Bond (LQD) – 3,271,938 shares, 72.31% of the total portfolio. Shares added by 54.10%SPDR Portfolio Intermediate Term Corporate Bond (SPIB) – 2,000,000 shares, 12.63% of the total portfolio. New PositioniShares Intermediate Credit Bond ETF (CIU) – 618,046 shares, 12.48% of the total portfolio. Shares added by 757.25%Vanguard Short-Term Corporate Bond ETF (VCSH) – 88,000 shares, 1.3% of the total portfolio. Shares added by 35.38%iShares 1-3 Year Credit Bond ETF (CSJ) – 65,470 shares, 1.28% of the total portfolio. New Purchase: SPDR

Top 5 Performing Stocks To Watch Right Now: Syndax Pharmaceuticals, Inc. (SNDX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was down, falling around 21 percent to $8.76 after the company issued updated results from Phase 2 ENCORE trial of entinostat in combo with KEYTRUDA.

  • [By ]

    Syndax (SNDX) is developing entinostat, a Class I HDAC inhibitor, for the treatment of solid tumors. Shares popped recently following the release of Syndax’s first quarter earnings results, but a bigger catalyst on the horizon is the upcoming ASCO oncology conference in June. Syndax is due to present updated data from the ENCORE-601 Phase 2 trial in melanoma and lung cancer.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *